NEW YORK (GenomeWeb) - Biocept reported after the close of the market Thursday that its first quarter revenues increased 47 percent year over year, primarily due to growing commercial test volume.

For the three months ended March 31, the company's total revenues rose to $221,369 from $150,002 the prior year's quarter.

The liquid biopsy firm said it tested 810 billable samples during the first quarter of 2016, up from 289 billable cases during the first quarter of 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.